NVS - Novartis AG

NYSE - NYSE Delayed Price. Currency in USD
80.96
+2.26 (+2.87%)
At close: 4:02PM EDT

80.95 +0.03 (0.04%)
Pre-Market: 8:02AM EDT

Stock chart is not supported by your current browser
Previous Close78.70
Open80.64
Bid80.88 x 2200
Ask80.93 x 900
Day's Range80.25 - 81.00
52 Week Range72.30 - 94.19
Volume3,036,406
Avg. Volume1,727,026
Market Cap207.579B
Beta0.86
PE Ratio (TTM)23.73
EPS (TTM)3.41
Earnings DateN/A
Forward Dividend & Yield2.98 (3.85%)
Ex-Dividend Date2018-03-06
1y Target Est88.16
Trade prices are not sourced from all markets
  • Texas Instruments CEO resigns, Ericsson soars, Novartis delays price hikes
    Yahoo Finance22 hours ago

    Texas Instruments CEO resigns, Ericsson soars, Novartis delays price hikes

    Texas Instruments, Ericsson, Novartis, Marriott and Uber are the companies to watch.

  • Reuters1 hour ago

    Trump thanks Novartis, Pfizer for not raising drug prices

    U.S. President Donald Trump thanked two major drug companies on Thursday for not raising their prices and said his administration was working toward substantially cutting prescription-drug prices. "Thank you to Novartis for not increasing your prices on prescription drugs. Earlier this month Trump was able to persuade Pfizer CEO Ian Read to defer the company's planned price hikes, explaining in a call the company had complicated the administration's drug pricing plans.

  • Reuters1 hour ago

    Trump thanks Novartis, Pfizer for not raising drug prices

    U.S. President Donald Trump thanked two major drug companies on Thursday for not raising their prices and said his administration was working toward substantially cutting prescription-drug prices. "Thank you to Novartis for not increasing your prices on prescription drugs. Earlier this month Trump was able to persuade Pfizer CEO Ian Read to defer the company's planned price hikes, explaining in a call the company had complicated the administration's drug pricing plans.

  • Bloomberg6 hours ago

    Novartis to Pay as Much as $1 Billion for Rights to Skin Drug

    Novartis AG agreed to buy the rights to a skin-disease drug from developers Galapagos NV and MorphoSys AG in a deal that could reach $1 billion as Chief Executive Officer Vas Narasimhan centers the Swiss drugmaker on developing innovative prescription medicines. Novartis will pay 95 million euros ($111 million) upfront and later payments of up to 850 million euros based on the drug reaching certain regulatory, commercial and sales goals, MorphoSys said in a statement Thursday. The payments will be split 50-50 between Mechelen, Belgium-based Galapagos and Planegg, Germany-based MorphoSys.

  • Reuters6 hours ago

    Novartis to pay 95 mln euros to Galapagos, MorphoSys for skin drug

    Novartis said on Thursday it will pay 95 million euros to Galapagos and MorphoSys to license a prospective medicine targeting the skin condition atopic dermatitis, as the Swiss drugmaker strengthens its ...

  • The Wall Street Journal12 hours ago

    [$$] Novartis Won’t Raise U.S. Drug Prices This Year

    Novartis AG won’t increase its U.S. drug prices for the rest of 2018, the Switzerland-based drugmaker said Wednesday, days after Pfizer Inc. took a similar step following criticism from President Donald Trump. In an interview, Novartis Chief Executive Vas Narasimhan said the company would evaluate its strategy for 2019 when it has more clarity on the pricing environment. Last week, Pfizer said it would defer some recent drug-price increases, reversing course after Mr. Trump criticized the company for its plans to raise the prices of more than 40 drugs.

  • Novartis Q2 Earnings Miss, Sales Top on Cosentyx, Entresto
    Zacks16 hours ago

    Novartis Q2 Earnings Miss, Sales Top on Cosentyx, Entresto

    Novartis (NVS) misses on Q2 earnings but beats sales on the back of continued momentum from Cosentyx and Entresto. Oncology franchise also exhibits strong growth.

  • TheStreet.com17 hours ago

    5 Big Biotech Stories to Watch

    President Trump's attack on large pharma companies over drug prices might have grabbed headlines recently, but that shouldn't distract from the firms and drugs that have been driving change and innovation in the biotech industry. Here's a rundown of some of the news from small to large companies in the past few weeks that could have a big impact on the biotechnology and pharmaceutical sectors. 1. Biogen's Alzheimer's drug trial results show promise Curing Alzheimer's disease has frustrated the healthcare industry for years after numerous failed attempts have been made to find a treatment, but Biogen Inc.

  • Reuters19 hours ago

    Novartis hints at 2018 outlook hike despite drug price freeze

    Novartis (NOVN.S) may ratchet up its 2018 sales outlook, its finance chief said on Wednesday, despite halting planned U.S. drug price hikes amid pressure on the industry from President Donald Trump's administration over the high cost of medicines. Shares in the Swiss drugmaker, whose decision to freeze prices this year in the world's largest drug market was mirrored by Pfizer (PFE.N), closed 2.5 percent higher in Zurich after the firm beat forecasts with second-quarter results.

  • Texas Instruments CEO resigns, Ericsson soars over Q2, Novartis delay price hikes
    Yahoo Finance Video22 hours ago

    Texas Instruments CEO resigns, Ericsson soars over Q2, Novartis delay price hikes

    Texas Instruments, Ericsson, Novartis, Marriott and Uber are the companies to watch.